Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Related Questions
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
What is your approach to preventing exercise-associated hyponatremia?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?
Do you recommend repeat kidney stone composition testing for a patient with recurrent nephrolithiasis who passed an additional stone but previously already had stone composition testing performed?
Do you check a fractional excretion of sodium in nonoliguric patients with AKI?
Do you recommend daily topical exit site antibiotic use for patients with a peritoneal dialysis catheter that is only currently being accessed for once weekly flushes?
Do you recommend checking a serum phosphorus level in patients with recurrent nephrolithiasis?
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
